Astellas partners with Insilico, Harvard; Zambon gets FDA's fast track status for lung drug
→ Another day, another Insilico deal. Weeks after unveiling a tie-up with Germany’s Boehringer Ingelheim — the prolific dealmaking powers-that-be at the Hong Kong-based AI startup have lured yet another high profile partner: Astellas.
As usual, no deal terms were disclosed. “Astellas itself is one of the leaders in computational chemistry and AI,” chief Alex Zhavoronkov told Endpoints News via email. “Many Big Pharma companies that are making a lot of noise saying that they are investing in AI often require a lot of work to educate them on generative chemistry and show the platform before closing a deal. But Astellas has some of the best people who understand how things work and have people we respect a lot.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.